Feel better.

It’s easy without mets. Darolutamide is now poised to give enzalutamide a run for its money in the treatment of non-metastatic castrate-resistant prostate cancer with suggestions of equal oncologic benefit at a lower cost of side effects. Pfizer responds with these patient-reported outcomes from PROSPER. Not surprisingly, compared to ADT alone, the addition of enzalutamide hastened hormonal deprivation symptoms while delaying pain progression and urinary and bowel symptoms. | Tombal, Lancet Oncol 2019